We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Updates Draft Guidance on Rare Pediatric Disease Priority Review Voucher Program
FDA Updates Draft Guidance on Rare Pediatric Disease Priority Review Voucher Program
Drugmakers have been given more clarity on the FDA’s definition of rare pediatric disease and the process for its priority review voucher program in agency draft revised guidance issued Monday.